This clinical trial is focused on studying a type of blood cancer called Chronic Lymphocytic Leukemia (CLL). The study will explore the effects of three different treatments: Venetoclax, Obinutuzumab, and Acalabrutinib. Venetoclax is taken orally in the form of film-coated tablets, while Obinutuzumab is given as an infusion, which means it is administered directly into the bloodstream. Acalabrutinib is also taken orally as film-coated tablets. The purpose of the study is to evaluate the risk of a condition called tumor lysis syndrome (TLS), which can occur when cancer cells break down rapidly, releasing their contents into the bloodstream.
Participants in the study will receive one of these treatments, either alone or in combination, to see how well they work in managing CLL. The study will also look at how the treatments affect the participants’ health, particularly focusing on the risk of TLS and other related conditions like hyperkalemia, which is a high level of potassium in the blood. The study will involve different periods of gradually increasing the dose of Venetoclax to find the best way to start treatment safely.
The trial will be conducted over several weeks, with participants being closely monitored by healthcare professionals. The study aims to provide valuable information on how to optimize the use of these medications in treating CLL, ensuring that patients receive the most effective and safe treatment possible. Participants will be assessed for any changes in their condition and any side effects they may experience during the course of the study.
France 
Greece 
Spain 
